{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population.","reportingStatus":"POSTED","timeFrame":"Up to approximately 281 weeks","title":"DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Participants"}